Cardiff Oncology, Inc. (CRDF)
Largest Insider Buys in Sector
CRDF Stock Price History Chart
CRDF Stock Performance
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for …
Insider Activity of Cardiff Oncology, Inc.
Over the last 12 months, insiders at Cardiff Oncology, Inc. have bought $41,100 and sold $0 worth of Cardiff Oncology, Inc. stock.
On average, over the past 5 years, insiders at Cardiff Oncology, Inc. have bought $388,008 and sold $657,020 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PACE GARY W (director) — $123,300.
The last purchase of 30,000 shares for transaction amount of $41,100 was made by PACE GARY W (director) on 2023‑12‑19.
List of Insider Buy and Sell Transactions, Cardiff Oncology, Inc.
| 2023-12-19 | director | 30,000 0.0671% | $1.37 | $41,100 | +89.78% | |||
| 2022-11-25 | Chief Executive Officer | 10,000 0.0236% | $1.43 | $14,300 | +14.39% | |||
| 2022-09-19 | director | 15,000 0.0327% | $1.64 | $24,525 | -7.51% | |||
| 2022-09-16 | Chief Financial Officer | 30,000 0.0682% | $1.56 | $46,710 | +1.27% | |||
| 2022-09-16 | director | 13,000 0.0296% | $1.56 | $20,233 | +1.27% | |||
| 2022-09-15 | director | 150,000 0.3544% | $1.71 | $256,500 | -4.49% | |||
| 2022-09-15 | director | 10,000 0.0237% | $1.72 | $17,168 | -4.49% | |||
| 2021-09-21 | director | 30,000 0.0764% | $6.75 | $202,500 | -58.36% | |||
| 2021-09-10 | Chief Financial Officer | 30,000 0.0779% | $6.47 | $194,000 | -54.92% | |||
| 2021-03-26 | director | 2,900 0.0081% | $10.32 | $29,933 | -37.55% | |||
| 2021-03-23 | director | 10,000 0.0273% | $10.23 | $102,300 | -37.74% | |||
| 2021-03-23 | director | 2,370 0.0066% | $10.42 | $24,689 | -37.74% | |||
| 2021-03-23 | Chief Executive Officer | 965 0.0027% | $10.34 | $9,980 | -37.74% | |||
| 2021-03-23 | Exec. VP and COO | 960 0.0026% | $10.31 | $9,898 | -37.74% | |||
| 2021-03-22 | director | 3,000 0.0083% | $10.95 | $32,850 | -40.92% | |||
| 2021-03-19 | director | 4,000 0.0101% | $10.82 | $43,271 | -45.21% | |||
| 2021-03-18 | director | 3,000 0.0083% | $10.55 | $31,660 | -38.95% | |||
| 2021-03-04 | director | 1,500 0.0041% | $9.27 | $13,898 | -29.09% | |||
| 2020-11-23 | Sale | Exec. VP and COO | 35,321 0.147% | $18.60 | $657,020 | -57.83% | ||
| 2020-09-16 | director | 2,550 0.0107% | $5.70 | $14,527 | +72.12% |
Insider Historical Profitability
| PACE GARY W | director | 697761 1.3646% | $2.51 | 8 | 0 | +78.54% |
| Hunter Robert Merrill | 10 percent owner | 5065004 9.9054% | $2.51 | 1 | 0 | |
| BRIDGER MANAGEMENT, LLC | 2968115 5.8046% | $2.51 | 7 | 0 | <0.0001% | |
| Sheinerman Kira | director | 909090 1.7779% | $2.51 | 1 | 0 | |
| CERRONE GABRIEL | director | 719526 1.4071% | $2.51 | 5 | 0 |
Institutional Investor Ownership
| The Vanguard Group | $10.26M | 4.3 | 1.92M | +0.49% | +$50,559.12 | <0.0001 | |
| Laurion Capital Management LP | $4.96M | 2.08 | 928,717 | +28.61% | +$1.1M | 0.04 | |
| Millennium Management LLC | $3.65M | 1.53 | 683,299 | New | +$3.65M | <0.01 | |
| BlackRock | $3.62M | 1.52 | 677,458 | -5.45% | -$208,430.90 | <0.0001 | |
| MAI Capital Management, LLC | $2.94M | 1.23 | 551,124 | +45.3% | +$917,486.71 | 0.03 |